Clinical Trial Update: A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma completed; results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• IMBRUVICA (IBRUTINIB)
• Rituximab (rituximab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2017-02-23